The Cancer Market Outlook to 2016

Publication date: June 2011

Keywords : osteoporosis, cancer

Introduction The global cancer market is becoming increasingly competitive, with two therapeutic classes, namely antineoplastics and cytostatic hormonal treatments, dominating this sector. This report presents leading products, developments, and market forecasts for each of these classes. Eighteen recently launched/late-stage pipeline products are discussed in detail. Features and benefits * Understand how recen...

Search ReportLinker

The Largest Collection of Market Research Reports

» 1.2 Million Industry Reports
» 450,000 Company Profiles

» 850,000 Market Briefings
» 40,000 Country Guides

From +200,000 authoritative sources

Introduction

The global cancer market is becoming increasingly competitive, with two therapeutic classes, namely antineoplastics and cytostatic hormonal treatments, dominating this sector. This report presents leading products, developments, and market forecasts for each of these classes. Eighteen recently launched/late-stage pipeline products are discussed in detail.

Features and benefits

* Understand how recent events are affecting the performance of major products, and how companies are confronting competitive market changes.
* Compare the franchises of the leading companies in the cancer market, and understand how the market share of these companies will change.
* Assess key pipeline products by indication, ongoing trials, recent product launches, and key developments in R&D.
* Identify the challenges faced by leading players, and understand how recent events will impact the performance of leading products.
* Gain insights into the forecasts of the leading marketed and pipeline products through to 2016.

Highlights

The key factor for growth of the cancer therapy market is the expansion of target indications. Most of the blockbuster drugs were launched for a narrow indication, but later gained approval for a wider range of indications.
Regardless of indication, the key challenge in ensuring the commercial success of pipeline drugs is to ascertain their integration into current treatment regimens either in combination with existing therapies or by demonstrating significant superiority over current treatments.
Pricing risk remains the key investment concern in cancer. Moreover, the level of scrutiny by payers regarding the cost-effectiveness of cancer treatments has intensified in recent years.

Your key questions answereds

* What will be the major growth indications and the accompanying growth drivers in the cancer market over the next 6 years?
* Which were the leading players in the cancer market in 2010?
* Which products will be the future growth drivers for the cancer health market?
* Which therapeutic categories are forecast to have the highest levels of commercial potential over the period 2010–16?
* Which companies are best positioned to succeed in the cancer market over the period 2010–16?

Pathology Industry in China

Executive Summary
Overview and epidemiology of women’s health
Global market analysis
Pipeline analysis
Competitive landscape
About the author
Disclaimer
Overview and epidemiology of women’s health
Summary
Introduction
Osteoporosis
Overview
Diagnosis treatment and management
Epidemiology
Forecast epidemiology
Hormonal contraception
Overview
Diagnosis treatment and management
Epidemiology
Forecast epidemiology
Hormone replacement therapies
Overview
Diagnosis, treatment and management
Infertility treatment
Overview
Diagnosis, treatment and management
Epidemiology
Forecast epidemiology
Global market analysis
Summary
Market analysis by geography
Market analysis by therapy area
Hormonal contraceptives
Osteoporosis treatment
Hormone replacement therapy (HRT)
Infertility treatment
Key events in women’s health market
Merck Serono sells women's health division to Teva
Gedeon Richter extends women's health franchise with PregLem acquisition
Boehringer Ingelheim discontinued the development of its female desire drug, flibanserin
Eli Lilly's arzoxifene misses secondary endpoint in critical osteoporosis trial
Bayer’s Yaz and Yasmin get US label update
Research deal between Bayer and Chinese hospital for women's health
Leading brand dynamics
Actonel (Risedronate) – Warner Chilcott, Sanofi
Evista (raloxifene) – Eli Lilly
Bonviva/Boniva (ibandronic acid) – Roche/GlaxoSmithKline
Premarin (conjugated estrogens) – Pfizer
Fosamax (alendronate) – Merck & Co
Yaz/Yasmin (drospirenone + ethinyl estradiol) – Bayer
Mirena (levonorgestrel) – Bayer
Gonal F (follitropin beta) – Merck KGaA
NuvaRing (ethinyl estradiol + etonogestrel) – Merck & Co.
Global women’s health sales forecast
Pipeline analysis
Summary
Introduction
Women’s health pipeline
Leading drugs in development
Profiles of key pipeline products
Prolia (denosumab) – Amgen
Viviant/Conbriza (bazedoxifene) – Pfizer
LCS (ultra low-dose levonorgestrel releasing IUD) – Bayer
Aprela (bazedoxifene and conjugated estrogen) – Pfizer
MK-0822 (odanacatib) – Merck
Elonva (corifollitropin alfa) – Merck
Nomac E2 (nomegestrol and estradiol) – Merck & Co.
WC3026/ Generess (norethindrone + ethinyl estradiol) – Warner Chilcott/Watson
Natazia/Qlaira (estradiol valerate and dienogest) – Bayer
SMC021 (synthetic oral salmon calcitonin) – Novartis
FC Patch Low (gestodene and ethinyl estradiol transdermal patch) – Bayer
DR2011 (progesterone vaginal ring) – Teva
EllaOne (ulipristal acetate) – HRA Pharma/Watson
Pipeline forecast of leading drugs in development
Competitive landscape
Summary
Introduction
Sales performance of leading players
Bayer
Marketed product portfolio
Pipeline analysis
Strategic and growth analysis
Merck & Co.
Marketed product portfolio
Pipeline analysis
Strategic and growth analysis
Eli Lilly
Marketed product portfolio
Pipeline analysis
Strategic and growth analysis
Warner Chilcott
Marketed product portfolio
Pipeline analysis
Strategic and growth analysis
Pfizer
Marketed product portfolio
Pipeline analysis
Strategic and growth analysis
Teva
Marketed product portfolio
Pipeline analysis
Strategic and growth analysis
Appendix
Scope
Key women’s health diseases covered in this report
Methodology
Epidemiology forecast
Market forecast
Epidemiology forecast
References
Journal articles
Conference proceedings
Important websites
Glossary/abbreviations

Cancer in China